Newsletter Signup

University Health Network Expands Relationship with Perimeter Medical Imaging

[Original article: perimetermed.com ]

World Renowned Cancer Centre Partners on Tumour Margin Assessment

Toronto, Canada: September 15, 2014 – Perimeter Medical Imaging Inc., a developer of real time imaging systems for in-surgery tumour margin assessment, today announced an expanded relationship with University Health Network (UHN), the largest hospital-based research program in Canada, which includes closer research ties and a unique risk-sharing partnership.

Perimeter has worked closely with the Princess Margaret Cancer Centre, a UHN hospital and recognized global leader in cancer research, to test the clinical capabilities of Perimeter’s ‘OTIS’ tumour margin assessment solution. Promising clinical results from the first trial have led to this expansion of the relationship which includes both additional clinical activities and a risk-sharing activity.

“Having better tumour margin assessment tools available to clinicians, especially for breast cancer cases, has the potential of significantly improving outcomes. UHN is committed to finding solutions in real clinical situations. The promising progress in the technology and clinical results have resulted in expanding our relationship with Perimeter”, said Mark Taylor, Director of Commercialization of UHN’s medical technology group, the Techna Institute. “UHN’s Technology Development and Commercialization group is constantly innovating on ways to better interact with industry partners and leverage the assets and know-how of the hospital. This ‘risk-sharing’ approach with Perimeter is a perfect example of this commitment to our patients, and to patients around the world.”

“We are thrilled to be increasing our already close relationship with UHN,” said Paul Weber, Perimeter’s President and CEO. “Princess Margaret Cancer Centre is a world leader in cancer research and the confidence that UHN has shown with this investment adds significant credibility to our solution. Through this collaboration we look forward to bringing solutions to the market which will save patients from unnecessary mental and physical trauma currently experienced by all lumpectomy patients and their families!”